The latest report by IMARC Group, titled “Pneumococcal Vaccine Market: Global Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2032,” offers a comprehensive analysis of the pneumococcal vaccine market report. The report also includes competitor and regional analysis, along with a breakdown of segments within the industry.
The global pneumococcal vaccine market size reached US$ 9.4 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 14.4 Billion by 2032, exhibiting a growth rate (CAGR) of 4.7% during 2024-2032.
Pneumococcal Vaccine Market Trends:
The global market is primarily driven by the increasing prevalence of pneumococcal infections, as rising cases elevate the demand for vaccines. Additionally, strong government initiatives promoting immunization programs play a critical role in propelling market growth. The growing awareness regarding the severe consequences of pneumococcal diseases further encourages vaccination uptake. Moreover, advancements in vaccine technology, improving the efficacy and reach of vaccines, are contributing significantly to the market's expansion.
Furthermore, a rise in public and private funding for vaccine development is fostering innovation in the sector. Besides, the growing elderly population, which is more susceptible to pneumococcal infections, is driving increased vaccine adoption. Additionally, the rise in pediatric vaccination programs is another important driver of market growth. Moreover, the inclusion of pneumococcal vaccines in national immunization schedules across various countries is supporting sustained market expansion.
Get a Sample Copy of this Report: https://www.imarcgroup.com/pneumococcal-vaccine-market/requestsample
Pneumococcal Vaccine Market Scope and Growth Analysis:
The market scope is broadening due to the rising investments in research and development that are accelerating the introduction of more effective vaccines, expanding their application across different age groups and populations. Furthermore, advancements in biotechnology are enabling the creation of vaccines that cover more strains of the pneumococcus bacterium, which is further supporting the market growth. Besides, the increasing trend of integrating pneumococcal vaccines into global immunization programs broadens their market scope significantly.
Additionally, healthcare infrastructure improvements in emerging economies are making vaccine distribution more accessible, allowing for broader market penetration. Public-private partnerships aimed at reducing vaccine costs and expanding their reach are also contributing to market expansion. Rising healthcare expenditure and enhanced vaccine production capabilities are further strengthening market prospects. Moreover, the market is set to grow with ongoing regulatory approvals of newer formulations, catering to a wider population base.
View Full Report with TOC List of Figure: https://www.imarcgroup.com/pneumococcal-vaccine-market
Competitive Landscape:
The competitive landscape of the market has been studied in the report with the detailed profiles of the key players operating in the market.
- Astellas Pharma Inc.
- GlaxoSmithKline Plc.
- Merck Co. Inc.
- Panacea Biotec Ltd.
- Pfizer Inc.
- Sanofi S.A.
- Serum Institute of India Pvt Ltd
- Walvax Biotechnology Co. Ltd.
Pneumococcal Vaccine Market Segmentation:
Our report has categorized the market based on region, vaccine type, product type, distribution channel and end user.
Breakup by Vaccine Type:
- Pneumococcal Conjugate Vaccine
- Pneumococcal Polysaccharide Vaccine
Breakup by Product Type:
- Prevnar 13
- Synflorix
- Pneumovax 23
Breakup by Distribution Channel:
- Distribution Partner Companies
- Non-Governmental Organizations (NGO)
- Government Authorities
Breakup by End User:
- Pediatrics
- Adults
Breakup by Region:
- North America (United States, Canada)
- Europe (Germany, France, United Kingdom, Italy, Spain, Others)
- Asia Pacific (China, Japan, India, Australia, Indonesia, Korea, Others)
- Latin America (Brazil, Mexico, Others)
- Middle East and Africa (United Arab Emirates, Saudi Arabia, Qatar, Iraq, Other)
Key highlights of the report:
- Market Performance (2018-2023)
- Market Outlook (2024-2032)
- Porter’s Five Forces Analysis
- Market Drivers and Success Factors
- SWOT Analysis
- Value Chain
- Comprehensive Mapping of the Competitive Landscape
About Us
IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.
IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.
Contact US:
IMARC Group
134 N 4th St. Brooklyn, NY 11249, USA
Email: sales@imarcgroup.com
Tel No:(D) +91 120 433 0800
United States: +1-631-791-1145
